Global detection and management of dysglycaemic patients with coronary artery disease results from the INTERASPIRE survey from 14 countries across six WHO regions
File(s)
Published version
Author(s)
Type
Journal Article
Abstract
Objective
Dysglycaemia, defined as type 2 diabetes mellitus (T2DM) or impaired glucose tolerance (IGT), increases the cardiovascular risk and prognosis. INTERASPIRE performed in 14 countries across 6 WHO regions evaluated guideline adherence and management of patients with coronary artery disease (CAD) and dysglycaemia.
Methods
A total of 4,548 CAD patients (18–80 years) were interviewed 6 months–2 years after hospital admission. All without diabetes were eligible for an oral glucose test (OGTT).
Results
Overall, 1990 (44%) had known T2DM. The OGTT revealed that 808 (40%) had previously unknown dysglycaemia (T2DM 12% and IGT 28%). Two thirds of all dysglycaemic patients were obese. A similar proportion reported low physical activity and only one third received dietary advice. Only half of dysglycemic patients were prescribed all guideline recommended cardioprotective drugs. A majority did not reach recommended blood pressure, lipids or HbA1c targets. Only 16% had attended a diabetes education program.
Conclusions
The INTERASPIRE study shows that screening for glucose perturbations in coronary patients is inadequate, achievement of lifestyle recommendations suboptimal and pharmacological management insufficient resulting in a poor risk factor control. Patients with coronary disease, especially those with glucose perturbations require professional support to achieve healthier lifestyles, and prescription of all cardioprotective medications to achieve guideline targets.
Dysglycaemia, defined as type 2 diabetes mellitus (T2DM) or impaired glucose tolerance (IGT), increases the cardiovascular risk and prognosis. INTERASPIRE performed in 14 countries across 6 WHO regions evaluated guideline adherence and management of patients with coronary artery disease (CAD) and dysglycaemia.
Methods
A total of 4,548 CAD patients (18–80 years) were interviewed 6 months–2 years after hospital admission. All without diabetes were eligible for an oral glucose test (OGTT).
Results
Overall, 1990 (44%) had known T2DM. The OGTT revealed that 808 (40%) had previously unknown dysglycaemia (T2DM 12% and IGT 28%). Two thirds of all dysglycaemic patients were obese. A similar proportion reported low physical activity and only one third received dietary advice. Only half of dysglycemic patients were prescribed all guideline recommended cardioprotective drugs. A majority did not reach recommended blood pressure, lipids or HbA1c targets. Only 16% had attended a diabetes education program.
Conclusions
The INTERASPIRE study shows that screening for glucose perturbations in coronary patients is inadequate, achievement of lifestyle recommendations suboptimal and pharmacological management insufficient resulting in a poor risk factor control. Patients with coronary disease, especially those with glucose perturbations require professional support to achieve healthier lifestyles, and prescription of all cardioprotective medications to achieve guideline targets.
Date Issued
2025-08-11
Date Acceptance
2025-07-21
Citation
Cardiovascular Diabetology, 2025, 24
ISSN
1475-2840
Publisher
BMC
Journal / Book Title
Cardiovascular Diabetology
Volume
24
Copyright Statement
© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/40790183
PII: 10.1186/s12933-025-02878-3
Subjects
Cardiac & Cardiovascular Systems
Cardiovascular prevention
Cardiovascular System & Cardiology
Coronary artery disease
Diabetes education program
Dysglycaemia
Endocrinology & Metabolism
EUROASPIRE IV
EUROPEAN-SOCIETY
GLUCOSE
HBA(1C)
INCOME COUNTRIES
Life Sciences & Biomedicine
MIDDLE-INCOME
MORTALITY TRENDS
Science & Technology
Screening
Type 2 diabetes
WORLD HEART FEDERATION
Publication Status
Published
Coverage Spatial
England
Article Number
327
Date Publish Online
2025-08-11